HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.

Trastuzumab has been approved for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction cancers (GC and GJC) in combination with chemotherapy. The aim of this HER2 early/advanced gastric epidemiology (HER-EAGLE) study was to evaluate the frequency of...

Полное описание

Библиографические подробности

Главные авторы:	Dan Huang, Ning Lu, Qinhe Fan, Weiqi Sheng, Hong Bu, Xiaolong Jin, Guimei Li, Yanhui Liu, Xianghong Li, Wenyong Sun, Huizhong Zhang, Xiaobing Li, Zongguang Zhou, Min Yan, Xuan Wang, Weihong Sha, Jiafu Ji, Xiangdong Cheng, Zhiwei Zhou, Jianming Xu, Xiang Du
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Public Library of Science (PLoS) 2013-01-01
Серии:	PLoS ONE
Online-ссылка:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0080290&type=printable
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!